Introduction
New fluoroquinolones have been widely used to treat various infections, because of their broad antibacterial spectra, bactericidal activities and good pharmacokinetics. 1 DU-6859a is a new fluoroquinolone with the chemical structure (-)-7-(7S)-amino-5-azaspiro(2,4)heptan-5-yl-8-chloro-6-fluoro-1-(1,2R)-cis-2-fluoro-1-cyclopropyl-1,4-dihydro-4-oxoquinolone-3-carboxylic acid, which was initially synthesized by Daiichi Pharmaceutical Co. Ltd, Tokyo, Japan.
2 DU-6859a displays relatively potent invitro activity compared with related quinolones. 3, 4 Polymicrobial infections caused by aerobes and anaerobes are commonly seen in the female genital tract. 5 We therefore evaluated the efficacy of two quinolones, DU6859a and levofloxacin, using a new model of rat uterine endometritis caused by organisms isloated from human endometritis. This is the first report of the in-vivo activity of DU-6859a.
Materials and methods

Animals
Female Sprague-Dawley rats (specific pathogen free, 11 weeks old, weighing 210-250 g) were used.
Organisms
Organisms were clinical isolates from patients with uterine endometritis. MICs were determined by a standard agar dilution method using Mueller-Hinton agar (Difco Laboratories, Detroit, MI, USA) for Escherichia coli, and Gifu anaerobic medium (GAM) agar (Kyokuto Pharmaceutical Co. Ltd, Tokyo, Japan) for Bacteroides fragilis.
6, 7 The MIC was defined as the lowest concentration of drug that prevented visible growth of bacteria. Aerobic and anaerobic organisms grown on agar plates were suspended in Mueller-Hinton broth (Difco) and GAM broth (Kyokuto) respectively, to obtain about 5 10 8 cfu/mL. After 200-fold dilution of the suspension, bacteria at a density of about 2.5 10 4 cfu per spot were inoculated on to agar plates containing each antimicrobial agent with a multipoint inoculator (Microplanter; Sakuma Seisakusho, Tokyo, Japan). All aerobic cultures were incubated at 37°C for 24 h, and all anaerobic cultures at 37°C for 48 h in a GasPak system (Becton-Dickinson, Cockeysville, MD, USA).
E. coli was grown on Mueller-Hinton agar (BectonDickinson) for 24 h, and B. fragilis on Brucella haemin, vitamin K 1 rabbit/sheep agar (Kyokuto) for 48 h. Anaerobic bacterial culture medium (ABCM) broth (Eiken Chemical Co., Ltd., Tokyo, Japan) was used for inoculation into the uterine cavity.
Rat uterine endometritis model
Rats were anaesthetized intraperitoneally with sodium pentobarbital at a dosage of 25 mg/kg. The abdominal and flank hair was shaved, and then the abdominal wall was thoroughly swabbed with povidone-iodine. A small © 1998 The British Society for Antimicrobial Chemotherapy JAC vertical incision was made in the abdominal wall, and uterus and adnexa were exposed. A sterile foreign body, a 1 mm 7 mm 1 mm part of an FD-1 intrauterine device (Fuji Latex Co. Ltd, Tokyo, Japan) was placed into the uterine cavity. Using a disposable sterile tuberculin syringe with a 27-gauge needle, 0.05 mL of bacterial suspension containing 1.1 10 5 cfu/rat of E. coli or 1.3 10 5 cfu/rat of B. fragilis was injected into the right side of uterine cavity. The abdominal wall was closed with 1-0 silk suture. After the operation, the abdominal wound was disinfected with povidone-iodine every day.
Therapeutic study
Sixteen hours after the intrauterine inoculation of 1.1 10 5 cfu/rat of E. colior 1.3 10 5 cfu/rat of B. fragilis, DU-6859a (20 mg/kg po bid) or levofloxacin (20 mg/kg po tid) was given to groups of three rats for 3 days. Control rats received no drug. The dose and frequency of administration had been determined in another study. 8, 9 Eighty-eight hours after bacterial inoculation, under anaesthesia with sodium pentobarbital, the peritoneal cavity was opened aseptically, and the right uterine corporis was resected. Part of it was subjected to histological examination, and most of the uterine corporis was homogenized and subjected to quantitative bacterial examinations. Quantitative bacterial cultures were performed on BTB agar (Eiken Chemical Co. Ltd) for E. coli and on bile-aesculin agar (Kyokuto) for Bacteroides.
Statistical analysis
Values are reported as mean standard deviation (S.D.). All results were analysed using the Bonferroni-Dunn test and significance was assigned at P 0.05.
Results and discussion
The Figure shows the histological effects of DU-6859a and levofloxacin on the rat uterine corporis in DU-6859a-treated, levofloxacin-treated and untreated groups. Infections were restricted to the uterus. The inflammatory reactions and leucocyte infiltration of the uterus in the treated groups were milder than those in the untreated group.
The MICs of DU-6859a and levofloxacin for E. coli GOG 0020 were 0.025 and 0.05 mg/L, respectively, and MICs of DU-6859a and levofloxacin for B. fragilis GOG 3101 were 0.20 and 0.39 mg/L, respectively.
The Table shows the bacteriological effects of DU-6859a and levofloxacin. The viable cell counts of E. coli and B. fragilis in the DU-6859a-and levofloxacin-treated groups were significantly lower than those in the untreated group.
Animal models can be indispensable for evaluating the therapeutic effects of antimicrobial agents, especially in studies of infectious diseases. Data from animal models often provide information that is valuable for human infectious diseases, dealing with bacterial virulence and therapeutic efficacy. There have been few but limited animal models of intrauterine infection. A model of pyometra has been tried, but was unsuccessful. 10 Since the pyometra model is a closed-phase one, it is similar to an in-vitro model. We believe that the endometritis model is better than the pyometra model for evaluating drug efficacy as it is closer to the clinical situation. Therefore, we designed a rat model of intrauterine infection in which a foreign body is used to promote persistence of endometrial infection.
These results suggest that DU-6859a, as well as levofloxacin, might be useful for treating polymicrobial infections in the clinical fields of obstetrics and gynaecology. 
